UPC_CFI_808/2025

DETECTION AND TREATMENT OF DISEASE EXHIBITING DISEASE CELL HETEROGENEITY AND SYSTEMS AND METHODS FOR COMMUNICATING TEST RESULTS

Provisional measuresProvisional MeasuresParis LDProvisional measuresOral Phase

Overview Decisions Reasoning Citations Documents Timeline

Parties

Claimants

Guardant Health, Inc.

Reps: Agathe Michel-De Cazotte (Carpmaels & Ransford); Cameron Marshall (Carpmaels & Ransford); Caroline Horstmann

Respondents

Sophia Genetics SA
Sophia Genetics SAS
Sophia Genetics SRL
Sophia Genetics GmbH

Reps: Liz Cohen (Bristows (Ireland) LLP); Naoise Gaffney (Bristows (Ireland) LLP); Rachael Cartwright (Bristows (Ireland) LLP)

Judges

French-seated division — individual judges anonymized.

Panel member (anonymized)
Panel member (anonymized)
Panel member (anonymized)
Panel member (anonymized)

Patents

EP3766986
EP3470533
EP3443066
EP3591073
EP 3 591 073
EP 3 443 066
EP 3 766 986
EP 3 470 533

CPC codes: C12Q1/6827, G16B30/00, C12Q2600/118, C12Q1/6886, C12N15/11, C12Q2600/156, C12Q1/6869

Sector: Biotechnology

Outcome

PI denied

Filed: Aug 29, 2025

First decided: Oct 1, 2025

Last decision: Jan 23, 2026

Language: English

The Paris Local Division rejected Guardant Health's application for provisional measures under three patents (EP 3 591 073, EP 3 443 066, EP 3 766 986) against Sophia Genetics. The court found issues of added matter in the divisional patent and insufficient evidence to demonstrate infringement with the required degree of certainty. Guardant Health's request regarding a fourth patent (EP 3 470 533) was withdrawn during proceedings. Guardant Health ordered to pay Sophia Genetics EUR 400,000 as interim costs.

Open on UPC Registry